Adial Pharmaceuticals Inc
adialpharma.comAdial Pharmaceuticals (NASDAQ: ADIL) is a clinical-stage biotechnology company focused on developing medications for alcohol use disorder (AUD) in patients with certain targeted genotypes. The company generates no product revenue. All operations are funded through capital raises, and as of December 31, 2025, Adial carried an accumulated deficit of approximately $90 million with a net loss of approximately $8.0 million for the year ended December 31, 2025. The lead program is ADO4, a genotype-targeted treatment for AUD, with a strategic collaboration framework agreement in place for a proposed partnership to commercialize ADO4 in Europe. Adial has six employees as of the 10-K filing date of March 5, 2026, five full-time and one consultant. Principal offices are in Glen Allen, Virginia. The company has no approved products, no commercial revenue, and expects continued operating losses for the foreseeable future.
Products & Services
ADO4, a genotype-targeted investigational drug for alcohol use disorder (AUD). The product is in clinical development and has not received regulatory approval.
Revenue Model
No product revenue has been generated to date (as of December 31, 2025). Operations are sustained through equity financing, including a purchase agreement with Alumni Capital LP dated December 13, 2024.
Customers & Markets
End market is treatment of alcohol use disorder in patients with specific genetic profiles. No commercial customers as of December 31, 2025.
Geographic Exposure
United States primary development base, with a proposed European commercialization partnership for ADO4 referenced in the 10-K filed March 5, 2026.
Financial Snapshot
Loading...
